Positive correlation of serum adiponectin with lipid profile in patients with type 2 diabetes mellitus is affected by metabolic syndrome status

Archives of Iranian Medicine

Volumn 19, Issue 4, 2016, Pages 269-274

  Eslamian, Mohammad ^a   Mohammadinejad, Payam ^a   Aryan, Zahra ^a,b   Nakhjavani, Manouchehr ^a   Esteghamati, Alireza ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Adiponectin; Lipid profile; Metabolic syndrome

Indexed keywords

ADIPONECTIN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DYSLIPIDEMIA; FEMALE; GENDER; HIP CIRCUMFERENCE; HUMAN; INSULIN RESISTANCE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; WAIST CIRCUMFERENCE; AGED; BLOOD; COMPLICATION;

ADIPONECTIN; ADULT; AGED; CHOLESTEROL, LDL; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; FEMALE; HUMANS; INSULIN RESISTANCE; LIPIDS; MALE; METABOLIC SYNDROME X; MIDDLE AGED;

EID: 84961872522     PISSN: 10292977     EISSN: 17353947     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Keaney Jr JF, Curfman GD, Jarcho JA. A Pragmatic View of the New Cholesterol Treatment Guidelines. New Engl J Med. 2014; 370(3): 275-278.
2. Lau DC, Dhillon B, Yan H, Szmitko PE, Verma S. Adipokines: molecular links between obesity and atheroslcerosis. Am J Physiol Heart CircPhysiol. 2005; 288(5): H2031-H2041.
3. Blaslov K, Bulum T, Zibar K, Duvnjak L. Relationship between adi-ponectin level, insulin sensitivity, and metabolic syndrome in type 1 diabetic patients. Int J Endocrinol. 2013; 2013:535906
4. Esteghamati A, Asnafi S, Eslamian M, Noshad S, Nakhjavani M. As-sociations of small dense low-density lipoprotein and adiponectin with complications of type 2 diabetes. Endocr Res. 2014; 40(1): 9-14.
5. Park M, Sweeney G. Direct effects of adipokines on the heart: focus on adiponectin. Heart Fail Rev. 2013 18(5): 631-644.
6. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA. 2004; 291(14): 1730-1737.
7. Kistorp C, Faber J, Galatius S, Gustafsson F, Frystyk J, Flyvbjerg A, et al. Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation. 2005; 112(12): 1756-1762.
8. von Frankenberg AD, do Nascimento FV, Gatelli LE, Nedel BL, Garcia SP, de Oliveira CS, et al. Major components of metabolic syndrome and adiponectin levels: a cross-sectional study. Diabetol Metab Syndr. 2014; 6(1): 26.
9. Qiao L, Zou C, van der Westhuyzen DR, Shao J. Adiponectin reduces plasma triglyceride by increasing VLDL triglyceride catabolism. Diabetes. 2008; 57(7): 1824-1833.
10. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes care. 2010; 33(Suppl 1): S62-S69.
11. Alberti K, Zimmet P, Shaw J. Metabolic syndrome-a new worldwide definition. A consensus statement from the international diabetes federation. Diabet Med. 2006; 23(5): 469-480.
12. Guenther M, James R, Marks J, Zhao S, Szabo A, Kidambi S. Adipos-ity distribution influences circulating adiponectin levels. Transl Res. 2014; 164(4): 270-277.
13. von Frankenberg AD, do Nascimento FV, Gatelli LE, Nedel BL, Garcia SP, de Oliveira CS, et al. Major components of metabolic syndrome and adiponectin levels: a cross-sectional study. Diabetol Metab Syndr. 2014; 6(1): 26.
14. Ryu HK, Yu SY, Park JS, Choi YJ, Huh KB, Park JE, et al. Hypoadi-ponectinemia is strongly associated with metabolic syndrome in Korean type 2 diabetes patients. J Am Coll Nutr. 2010; 29(3): 171-178.
15. Snijder MB, Heine RJ, Seidell JC, Bouter LM, Stehouwer CD, Nij-pels G, et al. Associations of adiponectin levels with incident impaired glucose metabolism and type 2 diabetes in older men and women: the hoorn study. Diabetes Care. 2006; 29(11): 2498-2503.
16. Dastani Z, Hivert MF, Timpson N, Perry JR, Yuan X, Scott RA, et al. Novel loci for adiponectin levels and their influence on type 2 diabetes and metabolic traits: a multi-ethnic meta-analysis of 45,891 individuals. PLoS Genet. 2012; 8(3): e1002607.
17. Esteghamati A, Aryan Z, Esteghamati A, Nakhjavani M. Vitamin D deficiency is associated with insulin resistance in nondiabetics and reduced insulin production in type 2 diabetics. Horm Metab Res. 2015; 47(4): 273-279.
18. Esteghamati A, Aryan Z, Esteghamati A, Nakhjavani M. Differences in vitamin D concentration between metabolically healthy and unhealthy obese adults: Associations with inflammatory and cardio-metabolic markers in 4391 subjects. Diabetes Metab. 2014; 40(5): 347-355.
19. Yan T, Li L, Wang H, Wang J, Cai D. Correlation between adipocyto-kines levels and metabolic syndrome in type 2 diabetes mellitus. Nan Fang Yi Ke DaXueXue Bao. 2014; 34(2): 275-278.
20. Bonneau GA, Pedrozo WR, Berg G. Adiponectin and waist circumference as predictors of insulin-resistance in women. Diabetes Metab Syndr. 2014; 8(1): 3-7.
21. Kazumi T, Kawaguchi A, Hirano T, Yoshino G. Serum adiponectin is associated with high-density lipoprotein cholesterol, triglycerides, and low-density lipoprotein particle size in young healthy men. Metabolism. 2004; 53(5): 589-593.
22. Mohan V, Deepa R, Pradeepa R, Vimaleswaran KS, Mohan A, Velmurugan K, et al. Association of low adiponectin levels with the metabolic syndrome--the Chennai Urban Rural Epidemiology Study (CURES-4). Metabolism. 2005; 54(4): 476-481.
23. Retnakaran R, Zinman B, Connelly PW, Harris SB, Hanley AJ. Non-traditional cardiovascular risk factors in pediatric metabolic syndrome. JPediatr. 2006; 148(2): 176-182.
24. Donath MY. Targeting inflammation in the treatment of type 2 diabetes: time to start. Nat Rev Drug Discov. 2014; 13(6): 465-476.
25. Wagner A, Simon C, Oujaa M, Platat C, Schweitzer B, Arveiler D. Adiponectin is associated with lipid profile and insulin sensitivity in French adolescents. Diabetes Metab. 2008; 34(5): 465-471.
26. Magge SN, Stettler N, Koren D, Levitt Katz LE, Gallagher PR, Mohler ER 3rd, et al. Adiponectin is associated with favorable lipoprotein profile, independent of BMI and insulin resistance, in adolescents. J Clin Endocrinol Metab. 2011; 96(5): 1549-1554.
27. Weiss R, Otvos JD, Flyvbjerg A, Miserez AR, Frystyk J, Sinnreich R, et al. Adiponectin and lipoprotein particle size. Diabetes Care. 2009; 32(7): 1317-1319.
28. Verges B. Lipid modification in type 2 diabetes: the role of LDL and HDL. Fundam Clin Pharmacol. 2009; 23(6): 681-685.
29. Kishida K, Funahashi T, Shimomura I. Adiponectin as a routine clinical biomarker. Best Pract Res Clin Endocrinol Metab. 2014; 28(1): 119-130.
30. Baldasseroni S, Antenore A, Di Serio C, Orso F, Lonetto G, Bartoli N, et al. Adiponectin, diabetes and ischemic heart failure: a challenging relationship. Cardiovasc Diabetol. 2012; 18; 11: 151.
31. Gray RS, Robbins DC, Wang W, Yeh JL, Fabsitz RR, Cowan LD, et al. Relation of LDL size to the insulin resistance syndrome and coronary heart disease in American Indians. The Strong Heart Study. Arte-rioscler Thromb Vasc Biol. 1997; 17(11): 2713-2720.